



Corrigendum: Safety Profiles of *Tripterygium wilfordii* Hook F: A Systematic Review and Meta-Analysis

Chi Zhang^{1,2}, Ping-Ping Sun³, Hong-Tao Guo⁴, Yan Liu¹, Jian Li³, Xiao-Juan He^{1,2} and Ai-Ping Lu^{2*}

¹ Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China, ² School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong, ³ School of Basic Medical Sciences, Beijing University of Chinese Medicine, Beijing, China, ⁴ The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China

Keywords: *Tripterygium wilfordii* Hook F, safety, adverse event, systematic review, meta-analysis

A corrigendum on

OPEN ACCESS

Edited and reviewed by:

Adolfo Andrade-Cetto,
National Autonomous University of
Mexico, Mexico

*Correspondence:

Ai-Ping Lu
aipinglu@hkbu.edu.hk

Specialty section:

This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 12 January 2017

Accepted: 30 January 2017

Published: 15 February 2017

Citation:

Zhang C, Sun P-P, Guo H-T, Liu Y,
Li J, He X-J and Lu A-P (2017)
Corrigendum: Safety Profiles of
Tripterygium wilfordii Hook F:
A Systematic Review and
Meta-Analysis.
Front. Pharmacol. 8:59.
doi: 10.3389/fphar.2017.00059

Safety Profiles of *Tripterygium wilfordii* Hook F: A Systematic Review and Meta-Analysis

by Zhang, C., Sun, P.-P., Guo, H.-T., Liu, Y., Li, J., He, X.-J., et al. (2016). *Front. Pharmacol.* 7:402. doi: 10.3389/fphar.2016.00402

In the original article, there was an error. “Aspirin” was referred to instead of “TwHF.”

A correction has been made to **the last sentence of the Results section in the abstract:**

We screened 4137 abstracts for eligibility and included 594 studies in the analysis. The overall incidence of AEs was 26.7% (95% CI 24.8%, 28.8%) in 23,256 TwHF users. The estimates did vary markedly when stratified by specific study types. The incidence of gastrointestinal symptoms, adverse reproductive outcomes, adverse skin reactions, hematologic events and cardiovascular events were 13.3% (95% CI 11.9%, 14.9%), 11.7% (95% CI 10.3%, 13.3%), 7.8% (95% CI 6.3–9.5%), 6.5% (95% CI 5.7–7.4 %) and 4.9% (95% CI 1.6 %, 14.3 %), respectively. The prevalence of irregular menstruation (IM) was increased in patients taking TwHF compared with those given control (odds ratio [OR] 4.65, 95% CI 3.08 to 7.03). TwHF use has lower risk of weight gain (OR 0.12 [95% CI 0.04 to 0.39]) and hair loss (OR 0.37 [95% CI 0.18 to 0.78]). Furthermore, long-term TwHF use (>6 months) has a higher AEs incidence (31.0% [95% CI 24.5%–38.5%]).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Zhang, Sun, Guo, Liu, Li, He and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.